Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920855 · ClinicalTrials.gov registry record · Phase 1
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Cephalon.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT00920855: Completed Phase 1 study of Multiple Myeloma, sponsored by Cephalon.
NCT00920855 is a Phase 1 study of Multiple Myeloma that has completed, run by Cephalon. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920855, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
Primary Outcome
Maximum tolerated dose was the dose that was 1 step lower than the dose where at least one third of patients experienced DLT. A DLT was defined as any of the following occurring during the first cycle: * grade 4 hematologic toxicity without regard for relationship to study drug treatment * thrombocytopenia grade 3 with grade 3 or grade 4 hemorrhage * grade 3 febrile neutropenia * grade 3 or grade 4 nausea and vomiting refractory to anti emetic therapy * any study drug related grade 3 or grade 4
Conditions Studied
Interventions
- DRUG bendamustine
- DRUG bortezomib
Study Locations (13)
California
- Pacific Oncololgy & Hematology - Encinitas
- Capitol Hematology Oncology - Roseville
- University Of California, San Diego - San Diego
- James R. Berenson, M.D., Inc. - West Hollywood
Maryland
- Alivin & Lois Lapidus Cancer Institute - Baltimore
- Center for Cancer and Blood Disorders - Bethesda
District of Columbia
- George Washington University - Washington D.C.
Illinois
- Northshore University Health System - Evanston
Massachusetts
- Sophia Gordon Cancer Center at Lahey Clinic - Burlington
Pennsylvania
- Geisinger Medical Center - Danville
South Carolina
- Charleston Hematology Oncology, PA - Charleston
Tennessee
- Family Cancer Center, PLLC - Collierville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00920855 record still lists
NCT00920855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which bendamustine is the first listed.
NCT00920855 lists 13 locations in 9 states (California, Maryland, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00920855 about?
NCT00920855 is a clinical study titled "Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma". The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT00920855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-06. Estimated completion is 2011-12.
What conditions does trial NCT00920855 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00920855?
The interventions under investigation include: bendamustine (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00920855?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920855 being conducted?
This trial has 13 study locations across California, District of Columbia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920855's enrollment target sits among peer trials
40 289th of 438 higher than 135 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia